Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: Preparation, characterization and in vitro evaluation

Nanomedicine

Volumn 2, Issue 2, 2007, Pages 219-232

  Betancourt, Tania ^a   Brown, Brandon ^b   Brannon Peppas, Lisa ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Breast cancer cells; Cancer; Controlled release; Doxorubicin; Drug delivery; Nanoparticles; Nanoprecipitation; Poly(lactic co glycolic acid)

Indexed keywords

DOXORUBICIN; NANOCARRIER; POLYMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INTERACTION; CELL PH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOPHARMACEUTICS; PRECIPITATION; PRIORITY JOURNAL; ZETA POTENTIAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BODY FLUIDS; CELL LINE, TUMOR; CELL SURVIVAL; DIFFUSION; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; FRACTIONAL PRECIPITATION; HUMANS; NANOSTRUCTURES;

EID: 34249815817     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.2.2.219     Document Type: Article

References (54)

1. Twardowski P, Margolin K: Targeting vascular endothellium with antibodies: In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy. Pagé M (Ed.). Humana Press Inc., Totowa, NJ, USA 199-210 (2002).
2. Lewis DH: Controlled release of bioactive agents from lactide/glycolide polymers: In: Biodegradable Polymers as Drug Delivery Systems. Chasin M, Langer R (Eds). Marcerl Dekker, New York, NY. USA 1-41 (1990).
3. Brannon-Peppas L: Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116(1), 1-9 (1995).
4. Blanco D, Alonso MJ: Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur. J. Pharm. Biopharm. 45(3), 285-294 (1998).
5. Fattal E, Pecquet S, Couvreur P, Andremont A: Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int. J. Pharm. 242(1-2), 15-24 (2002).
6. Murillo M. Goni MM, Irache HM, Arangoa MA, Blasco JM, Gamazo C: Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing brucella ovis antigens. J. Control. Release 85(1-3), 237-246 (2002).
7. Shive MS, Anderson JM: Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28(1), 5-24 (1997).
8. Freitas S, Merkle HP, Gander B: Microencapsulation by solvent extraction/ evaporation: reviewing the state of art of microsphere preparation process technology. J. Control. Release. 102(2) 313-332 (2005).
9. Astete CE, Sabilov CM: Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247-289 (2006).
10. Davda J, Labhasetwar V: Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233(1-2), 51-59 (2002).
11. Panyam J. Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3). 329-347 (2003).
12. Jain RA: The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21(23), 2475-2490 (2000).
13. Birnbaum DT, Kosmala JD, Brannon-Peppas L: Optimization of preparation techniques for poly(lactic acid-co-glycolic acid) nanoparticles. J. Nanopart. Res. 2(2), 173-181 (2000).
14. Brannon-Peppas L, Birnbaum DT: Process to scale-up the production of biodegradable nanoparticies. American Institute of Chemical Ergineers Annual Meeting. Los Angeles. CA, USA, November 12-17, 2000.
15. Yokoyama M, Okano T: Targetable drug carriers: present status and future perspectives. Adv. Drug Deliv. Rev. 21(2), 77-80 (1996).
16. Torchilin VP: Strategies and means for drug targeting: an overview: In: Biomedical Aspects of Drug Targeting. Muzykantov VR, Torchilin VP (Eds). Kluwer Academic Publishers, 3-26 (2002).
17. McDonald DM, Baluk P: Significance of blood vessel leakiness in cancer. Cancer Res. 62(18), 5381-5385 (2002).
18. Folkman J: Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3(7), 643-651 (2003).
19. Folkman J, Meder E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133(2), 275-288 (1971).
20. Blasiak J. Gioc E, Warszawski M: A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone. Acta Biochim. Polon. 49(1), 145-155 (2002).
21. IARC: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Some Naturally Occurring Substances. IARC, Lyon, France 353 (1976).
22. Lum BL, Svec JM, Torti FM: Doxorubicin:. alteration of dose scheduling as a means of reducing cardiotoxicity. Drug Intell. Clin. Pharm. 19(4), 259-264 (1985).
23. Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into anew form of chemotherapy. Cancer Invest. 19(4), 424-436 (2001).
24. Barraud L, Merle P, Soma E et al.: Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticies for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42, 736-343 (2005).
25. Ike O, Shimizu Y, Ikada Y et al.: Biodegradation and antitumor effect of adriamycin-containing poly(L-lactid acid) microspheres. Biomaterials 12(8), 757-762 (1991).
26. Lin R, Ng LS, Wang C-H: In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 26, 4476-4485 (2005).
27. Tan EC, Lin R, Wang C-H: Fabrication of double-walled microspheres for sustained release of doxorubicin. J. Colloild Interface Sci. 291, 134-143 (2005).
28. Yoo HS, Oh JE, Lee KH, Park TG: Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16(7), 1114-1118 (1999).
29. Yoo HS, Park TG: Biodegradable polymeric micetles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release 70(1-2), 63-70 (2001).
30. Zhang Z, Lee SH, Feng S-S: Folate-decorated poly(lactic-co-glycolide)-vitamin E TPGS nanoparticies for targeted drug delivery. Biomaterials 28(10), 1889-1899 (2007).
31. Yoo HS, Park TG: Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96(2), 273-283 (2004).
32. Lee ES, Na K, Bae YH: Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103(2), 405-418 (2005).
33. Jeong Y-I, Na H-S, Oh J-S, Choi K-C, Song C-E, Lee H-C: Adriamycin release from self-assembling nanospheres of poly(D,L-lactide-co-glycolide)-grafted pullulan. Int. J. Pharm. 322(1-2), 154-160 (2006).
34. Nasongkla N, Bey E, Ren J et al.: Multifunctional polymeric micelles as cancer-targed, MRI-ultrasensitive drug delivery systems. Nano Lett. 6(11), 2427-2430 (2006).
35. Leo E, Contado C, Bortolotti F et al.: Nanoparticle formulation may affect the stabilization of an antischemic prodrug. Int. J. Pharm. 307(1), 103-113 (2006).
36. Arica B, Lamprecht A: In vitro evaluation of betamethasone-loaded nanoparticles. Drug Dev. Ind. Pharm. 31(1), 19-24 (2005).
37. Stolnik S, Dunn SE, Garnett MC et al.: Surface modification of poly(lactide-co-glycolide nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 11(12), 1800-1808 (1994).
38. Peltonen L, Koistinen P, Hirvonen J: Preparation of nanoparticles by the nanoprecipitation of low molecular weight poly(1)lactide. STP Pharma Sci. 13(5), 299-304 (2003).
39. Furtado Mosquera VC, Legrand P, Pinto-Alphandary H, Puisieux F, Barratt G: Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physiochemical and structural properties. J. Pharm. Sci. 89(5), 614-626 (2000).
40. Barichello JM, Morishita M, Takayama K, Nagai T: Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm. 25(4), 471-476 (1999).
41. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V: Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticies. Int. J. Pharm. 262(1-2), 1-11 (2003).
42. Chapman AP: PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54(4), 531-545 (2002).
43. Heurtault B, Saulnier P, Pech B. Proust J-E, Benoit J-P: Physico-chemical stability of colloidal lipid particles. Biomaterials 24, 4283-4300 (2003).
44. Akiyoshi K. Taniguchi I. Fukui H, Sunamoto J: Hydrogel nanoparticle formed by self-assembly of hydrophobized polysaccharide. Stabilization of Adriamycin by complexation. Eur. J. Pharm. Biopharm. 42(4), 286-290 (1996).
45. Xu J-P, Ji J, Chen W-D, Shen J-C: Novel biomimetic polymersomes as polymer therapeutics for drug delivery. J. Control. Release 107(3), 502-512 (2005).
46. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ: Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73(2-3), 255-267 (2001).
47. Brannon-Peppas L: Polymers in controlled drug delivery. Med. Plastics Biomater. Mag. 4, 34-44 (1997).
48. Sturgeon RJ, Schulman SG: Electronic absorption spectra and protolytic equilibria of doxorubicin: direct spectrophotometric determination of microconstants. J. Pharm. Sci. 66(7), 958-961 (1977).
49. Birnbaum DT. Brannon-Peppas L: Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl. J. Biomater. Sci. Polym. Ed. 14(1), 87-102 (2003).
50. Couvreur P, Dubernet C, Puisieux F: Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41(1), 2-13 (1995).
51. Legrand P, Barratt G, Mosqueira V, Fessi H. Devissaguet JP: Polymeric nanocapsules as drug delivery systems. STP Pharma Sci. 9(5), 411-418 (1999).
52. Verrecchia T. Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M: Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Release 36(1-2), 49-61 (1995).
53. Verrecchia T, Huve P, Bazile D, Veillard M, Spenlehauer G, Couvreur P: Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation technique. J. Biomed. Mater. Res. 27(8), 1019-1028 (1993).
54. Bazile DV, Ropert C, Huve P et al.: Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13(15), 1093-1102 (1992).